Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | KLK7 | P49862 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203720 | 1.00 | PPARA (0.56) | PPARAPPARGSYKCTSSCTSK | |
| SCHEMBL2707177 | 1.00 | PPARA (0.56) | PPARAPPARGSYKCTSSCTSK | |
| SCHEMBL27578688 | 0.93 | PPARA (0.56) | PPARAPPARGSYKCTSSCTSK | |
| SCHEMBL10054776 | 0.93 | PPARA (0.56) | PPARAPPARGSYKCTSSCTSK | |
| Glutamic Acid SCHEMBL4669203 | 0.92 | PPARA (0.52) | PPARAPPARGSYKCTSSCTSK | |
| SCHEMBL1517760 | 0.91 | PPARA (0.55) | PPARAPPARGSYKCTSSCTSK | |
| SCHEMBL3817109 | 0.91 | PPARA (0.55) | PPARAPPARGSYKCTSSCTSK | |
| SCHEMBL14674671 | 0.91 | CTSS (0.54) | PPARAPPARGSYKCTSSCTSK | |
| SCHEMBL15083152 | 0.90 | PPARA (0.54) | PPARAPPARGSYKCTSSCTSK | |
| SCHEMBL10883348 | 0.90 | PPARA (0.54) | PPARAPPARGSYKCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109665-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4638745-A1 | NOVEL FAS RNAI THERAPEUTICS AND USES THEREOF | Eli Lilly and Company (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4638747-A1 | NOVEL RNA THERAPEUTICS AND USES THEREOF | Eli Lilly and Company (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-14 | — | — | US | disclosed |
| US-5166316-A | Polypeptides for genetic engineering | AKIRA KAJI (JP) | 1992-11-24 | — | — | US | disclosed |
| US-5116861-A | Treatment of Hypertension and Angina Pectoris | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-05-26 | — | — | US | disclosed |
| EP-0474273-A2 | A polypeptide capable of interacting with thrombin | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1992-03-11 | — | — | EP | disclosed |
| EP-0423649-A1 | Peptides and use thereof | Kuraray Co., Ltd. (JP) | 1991-04-24 | — | — | EP | disclosed |
| EP-0412699-A2 | Nitrosothiol derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-02-13 | — | — | EP | disclosed |
| US-4806557-A | Dihydropyridines and use thereof in treating hypertension and ischaemia | PFIZER INC. (US) | 1989-02-21 | — | — | US | disclosed |
| US-4629736-A | HIGH FIBRINOLYTIC ACTION; WATER SOLUBILITY; ANTICOAGULANTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-12-16 | — | — | US | disclosed |
| EP-0137640-A1 | Chain extended analogues of methotrexate and aminopterin | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1985-04-17 | — | — | EP | disclosed |
| EP-0136879-A2 | Fatty acid derivatives and processes of producing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1985-04-10 | — | — | EP | disclosed |
| EP-0074761-A1 | Peptide-type substrates useful in the quantitative determination of endotoxin | WHITTAKER CORPORATION (US) | 1983-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | PPARA 2736/4885PPARG 2549/4885SYK 3558/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | PPARA 2794/4885PPARG 3131/4885SYK 3527/4885 |
| US-20260109665-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | CBR1, CYP7A1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PPARA 3710/4885PPARG 3270/4885SYK 3491/4885 |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | DNPEP, VIP, NPEPPS | PPARA 2297/4885PPARG 3531/4885SYK 4233/4885 |
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | NGLY1, NPPA, VIP | PPARA 3049/4885PPARG 4325/4885SYK 2174/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | PPARA 3215/4885PPARG 3973/4885SYK 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.